<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">Ribavirin is administered intravenously 2–3 times/day at a dose of 500 mg to the adults in combination with IFN α or lopinavir/ritonavir. IFN-α is a broad-spectrum antiviral which is tested in vitro against SARS-CoV and proved effective in inhibiting its reproduction [
 <xref ref-type="bibr" rid="CR23">23</xref>]. Lopinavir/ritonavir which is a medicine for the human immunodeficiency virus (HIV) is promising against SARS-CoV at in vitro trial [
 <xref ref-type="bibr" rid="CR4">4</xref>].
</p>
